Scarica l'app Stockscreener
202.04
1.78%
-3.67
Dopo l'orario di chiusura:
202.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BDX Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$205.71
Aprire:
$206.4
Volume 24 ore:
2.57M
Relative Volume:
1.24
Capitalizzazione di mercato:
$58.01B
Reddito:
$20.64B
Utile/perdita netta:
$1.73B
Rapporto P/E:
33.56
EPS:
6.02
Flusso di cassa netto:
$2.94B
1 W Prestazione:
+0.60%
1M Prestazione:
-10.59%
6M Prestazione:
-16.45%
1 anno Prestazione:
-13.92%
Intervallo 1D:
$201.47
$206.78
Intervallo di 1 settimana:
$193.03
$209.95
Portata 52W:
$193.03
$251.99
Becton Dickinson Co Stock (BDX) Company Profile
Nome
Becton Dickinson Co
Settore
Industria
Telefono
(201) 847-6800
Indirizzo
ONE BECTON DR, FRANKLIN LAKES
Confronta BDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
202.04 | 58.01B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ISRG
Intuitive Surgical Inc
|
488.27 | 174.93B | 8.35B | 2.32B | 1.30B | 6.41 |
|
ALC
Alcon Inc
|
91.42 | 45.22B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
213.97 | 31.43B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
77.80 | 15.49B | 3.90B | 392.30M | 288.10M | 1.95 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-24 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-05-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-04-12 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-01-03 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-12-12 | Aggiornamento | Citigroup | Sell → Neutral |
| 2022-07-11 | Downgrade | Citigroup | Neutral → Sell |
| 2022-06-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-18 | Ripresa | Raymond James | Mkt Perform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2021-12-08 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-25 | Iniziato | Barclays | Equal Weight |
| 2020-12-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-12-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-07-09 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-06-01 | Ripresa | Goldman | Buy |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-07 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-02-07 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-02-07 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-02-06 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-01-08 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-05-13 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-12-07 | Iniziato | Deutsche Bank | Buy |
| 2018-10-16 | Iniziato | Barclays | Equal Weight |
| 2018-06-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-04-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-01-19 | Ripresa | BofA/Merrill | Buy |
| 2018-01-05 | Aggiornamento | Citigroup | Sell → Neutral |
| 2018-01-05 | Iniziato | KeyBanc Capital Mkts | Overweight |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2017-12-29 | Reiterato | Deutsche Bank | Buy |
Mostra tutto
Becton Dickinson Co Borsa (BDX) Ultime notizie
Becton Dickinson in talks with Thermo Fisher, Danaher to divest life sciences unit, FT reports - MSN
Immunoassay Analyzers Market Size to Hit USD 10.16 Billion by 2032 | SNS Insider - GlobeNewswire Inc.
BD to acquire Bard - The Covington News
Becton, Dickinson and Co. : BD Appoints Christopher Reidy as Chief Financial Officer - MarketScreener
Becton Dickinson EVP Michael Garrison sells $94,497 in stock - Investing.com Australia
Becton Dickinson EVP Michael Garrison sells $94,497 in stock By Investing.com - Investing.com Canada
Becton Dickinson and : BD Receives FDA 510(k) Clearance for Advanced Microbiology Solution - MarketScreener
Becton Dickinson's SWOT analysis: med tech giant's stock poised for growth - Investing.com
BD Seeks Potential Buyers for Life Sciences Business Division - Yahoo Finance
Citigroup Adjusts Becton Dickinson and Co. Price Target to $270 From $275, Maintains Buy Rating - MarketScreener
Becton, Dickinson Becomes Oversold - Nasdaq
Should You be Confident in Becton, Dickinson and Company’s (BDX) Ability to Deliver Long-Term Returns? - Yahoo
BD reports pay increases for some execs, decreases for others - Medical Design & Outsourcing
BD to Announce Financial Results for its Second Quarter of Fiscal 2025 - Quantisnow
Vascular Access Device Market Growth is Driven by Ongoing Research and Development in the Industry, Key Players -Becton, Dickinson and Company, - Global Banking | Finance | Review
Report: BD is in talks with competitors to sell Life Sciences biz - MassDevice
Becton Dickinson in talks to divest life sciences unit, FT reports - MarketScreener
Becton Dickinson in talks with Thermo Fisher, Danaher to divest life sciences unit, FT reports - MarketScreener
Becton Dickinson In Talks With Rivals Over Divesting Life Sciences Unit- FT - MarketScreener
Becton Dickinson in talks with rivals over divesting life sciences unit - Financial Times
BD Named One of America's Most Innovative Companies by Fortune - Quantisnow
Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline - Seeking Alpha
Here’s What Positions Becton, Dickinson and Company (BDX) Favorably in the Health Care Sector - Yahoo Finance
BD Names Gregory J. Hayes to Board of Directors - Quantisnow
BD Names Gregory J. Hayes to Board of Directors – Company Announcement - Financial Times
Goldman Sachs Adjusts PT on Becton Dickinson and Co. to $256 From $253, Keeps Buy Rating - Marketscreener.com
Goldman Sachs Adjusts PT to Becton Dickinson and Co. to $256 From $253, Keeps Buy Rating - MarketScreener
Was Jim Cramer Right About Becton, Dickinson and Company (BDX)? - Insider Monkey
Insider Sell: Richard Byrd Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus.com
FDA tags Becton, Dickinson and Company infusion software recall as Class I - Yahoo Finance
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term - Yahoo Finance
Becton Dickinson and : BD Announces Results for 2019 Second Fiscal Quarter; Updates Fiscal 2019 Guidance - MarketScreener
Becton, Dickinson Treats First Breast Revision Patient in GalaFlex Lite Scaffold Trial -March 20, 2025 at 07:56 am EDT - MarketScreener
BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery - Quantisnow
Becton, Dickinson and Company Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE? Scaffold in Breast Implant Revision Surgery - Marketscreener.com
Correction: Software for Alaris Systems Manager and CCE Adapter - fda.gov
Becton Dickinson EVP Richard Byrd sells $105,570 in stock By Investing.com - Investing.com Australia
Becton Dickinson EVP Richard Byrd sells $105,570 in stock - Investing.com
SEC Form 144 filed by Becton Dickinson and Company - Quantisnow
Here's Why Becton Dickinson (BDX) is a Strong Momentum Stock - Yahoo Finance
How Do Investors Really Feel About Becton Dickinson?Becton Dickinson (NYSE:BDX) - Benzinga
Becton, Dickinson, And Company Stock: Is BDX Underperforming The Healthcare Sector? - Barchart.com
Becton, Dickinson, and Company Stock: Is BDX Underperforming the Healthcare Sector? - Inkl
Becton, Dickinson and Company (NYSE:BDX) Stock Price Down 0.3% Following Insider Selling - Defense World
Becton Dickinson EVP Richard Byrd sells $436,325 in stock By Investing.com - Investing.com South Africa
Becton Dickinson EVP Richard Byrd sells $436,325 in stock - Investing.com India
Becton Dickinson Co Azioni (BDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):